Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Light Sciences raises $40.1mm via Series C

Executive Summary

Light Sciences Oncology (light-activated cancer drug therapy) raised $40.1mm through a Series C private placement to undisclosed investors. The company is planning to use the proceeds to continue development of its Litx (Light Infusion Therapy) candidate, which is in Phase III for hepatocellular carcinoma and metastatic colorectal cancer. Other Phase III trials are also set for brain cancer, as well as Phase I/II studies for benign prostatic hyperplasia.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies